{
  "first_published_at": "2010-10-11", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON096814", 
  "title": "Implanon contraceptive implant: changing to Nexplanon", 
  "tags": "{\"parsed_therapeutic\": [\"obstetrics-gynaecology-fertility\"], \"Audience:\": [\"Primary care\"], \"Therapeutic area:\": [\"Obstetrics, gynaecology and fertility\"]}", 
  "_document_number": 178, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/dose_icon.png", 
  "therapeutic_area": [
    "obstetrics-gynaecology-fertility"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Implanon contraceptive implant: changing to Nexplanon</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: October 2010</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>In October 2010, Nexplanon replaces the Implanon contraceptive implant. Nexplanon is a radio-opaque version with a new insertion mechanism. All healthcare professionals who are trained in inserting Implanon will need to make sure they are trained in using Nexplanon before the changeover. This should include model-arm training with a placebo implant<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<h2>Subdermal contraceptive implants containing etonogestrel</h2><p>To date, the only available subdermal implant used for contraception in the UK has been Implanon, which contains 68 mg etonogestrel. In October this year, a new product&mdash;called Nexplanon&mdash;replaces Implanon. Nexplanon also contains 68 mg etonogestrel and is bioequivalent to Implanon. Similar to Implanon, Nexplanon can be used for up to 3 years, and is removed in the same way as Implanon.</p><h2>What is changing?</h2><p>Nexplanon differs from Implanon in two ways:</p><ul>\r\n\t\t\t<li>it has a new preloaded applicator, designed to reduce the risk of insertion errors</li>\r\n\t\t\t<li>it is radio-opaque (it contains barium) and can therefore be located on an X-ray or CT scan, if necessary<br></li></ul><h2>Actions required: currently trained Implanon inserters</h2><p>Practitioners who currently insert Implanon should become familiar with the new Nexplanon, and should complete both theoretical and practical training before attempting to use it. An online visual training programme includes animation of the insertion technique. Once completed, model-arm training with a placebo implant is strongly recommended.&nbsp;Further details about the training programme and how to obtain placebo devices can be found on the manufacturer&rsquo;s website: <a href=\"http://www.nexplanon.co.uk/training\">www.nexplanon.co.uk/training</a>, or by contacting 0844 556 1444. Further details about training can also be found at the Faculty of Sexual and Reproductive Healthcare website <a href=\"http://www.ffprhc.org.uk/\" target=\"_blank\">www.ffprhc.org.uk</a><a href=\"http://www.ffprhc.org.uk/\">/</a></p><h2>What will happen to current stock of Implanon?</h2><p>Implanon will now be discontinued. However, you can continue to prescribe, dispense, or fit any remaining Implanon stock you may have.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong><br></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>It is essential that trained inserters of Implanon obtain practical and theoretical experience before changing to Nexplanon. This should include model-arm training with a placebo implant</li>\r\n\t\t\t</ul></div><p>See also <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON096743\" target=\"_blank\">letter for healthcare professionals sent September 2010</a>.</p><p>Nexplanon is also our highlighted Patient Information Leaflet of the month (see article O1).</p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update Oct 2010, vol 4 issue 3: A1.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<h2>Subdermal contraceptive implants containing etonogestrel</h2><p>To date, the only available subdermal implant used for contraception in the UK has been Implanon, which contains 68 mg etonogestrel. In October this year, a new product&#8212;called Nexplanon&#8212;replaces Implanon. Nexplanon also contains 68 mg etonogestrel and is bioequivalent to Implanon. Similar to Implanon, Nexplanon can be used for up to 3 years, and is removed in the same way as Implanon.</p><h2>What is changing?</h2><p>Nexplanon differs from Implanon in two ways:</p><ul>\r\n\t\t\t<li>it has a new preloaded applicator, designed to reduce the risk of insertion errors</li>\r\n\t\t\t<li>it is radio-opaque (it contains barium) and can therefore be located on an X-ray or CT scan, if necessary<br></li></ul><h2>Actions required: currently trained Implanon inserters</h2><p>Practitioners who currently insert Implanon should become familiar with the new Nexplanon, and should complete both theoretical and practical training before attempting to use it. An online visual training programme includes animation of the insertion technique. Once completed, model-arm training with a placebo implant is strongly recommended.&#160;Further details about the training programme and how to obtain placebo devices can be found on the manufacturer&#8217;s website: <a href=\"http://www.nexplanon.co.uk/training\">www.nexplanon.co.uk/training</a>, or by contacting 0844 556 1444. Further details about training can also be found at the Faculty of Sexual and Reproductive Healthcare website <a href=\"http://www.ffprhc.org.uk/\" target=\"_blank\">www.ffprhc.org.uk</a><a href=\"http://www.ffprhc.org.uk/\">/</a></p><h2>What will happen to current stock of Implanon?</h2><p>Implanon will now be discontinued. However, you can continue to prescribe, dispense, or fit any remaining Implanon stock you may have.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong><br></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>It is essential that trained inserters of Implanon obtain practical and theoretical experience before changing to Nexplanon. This should include model-arm training with a placebo implant</li>\r\n\t\t\t</ul></div><p>See also <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON096743\" target=\"_blank\">letter for healthcare professionals sent September 2010</a>.</p><p>Nexplanon is also our highlighted Patient Information Leaflet of the month (see article O1).</p><p>&#160;</p><p><em>Article citation: Drug Safety Update Oct 2010, vol 4 issue 3: A1.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2010-10-01", 
  "date_last_modified": "2011-01-14", 
  "_assets": [], 
  "_item_id": 178, 
  "summary": "In October 2010, Nexplanon replaces the Implanon contraceptive implant. Nexplanon is a radio-opaque version with a new insertion mechanism. All healthcare professionals who are trained in inserting Implanon will need to make sure they are trained in using Nexplanon before the changeover. This should include model-arm training with a placebo implant", 
  "body": "Article date: October 2010\n\n## Subdermal contraceptive implants containing etonogestrel\n\nTo date, the only available subdermal implant used for contraception in the UK has been Implanon, which contains 68 mg etonogestrel. In October this year, a new product—called Nexplanon—replaces Implanon. Nexplanon also contains 68 mg etonogestrel and is bioequivalent to Implanon. Similar to Implanon, Nexplanon can be used for up to 3 years, and is removed in the same way as Implanon.\n\n## What is changing?\n\nNexplanon differs from Implanon in two ways:  \n  \n  * it has a new preloaded applicator, designed to reduce the risk of insertion errors  \n  * it is radio-opaque (it contains barium) and can therefore be located on an X-ray or CT scan, if necessary  \n  \n  \n## Actions required: currently trained Implanon inserters\n\nPractitioners who currently insert Implanon should become familiar with the new Nexplanon, and should complete both theoretical and practical training before attempting to use it. An online visual training programme includes animation of the insertion technique. Once completed, model-arm training with a placebo implant is strongly recommended. Further details about the training programme and how to obtain placebo devices can be found on the manufacturer’s website: [www.nexplanon.co.uk/training](http://www.nexplanon.co.uk/training), or by contacting 0844 556 1444. Further details about training can also be found at the Faculty of Sexual and Reproductive Healthcare website [www.ffprhc.org.uk](http://www.ffprhc.org.uk/)[/](http://www.ffprhc.org.uk/)\n\n## What will happen to current stock of Implanon?\n\nImplanon will now be discontinued. However, you can continue to prescribe, dispense, or fit any remaining Implanon stock you may have.\n\nAdvice for healthcare professionals:  \n  \n  \n  * It is essential that trained inserters of Implanon obtain practical and theoretical experience before changing to Nexplanon. This should include model-arm training with a placebo implant  \n  \nSee also [letter for healthcare professionals sent September 2010](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON096743).\n\nNexplanon is also our highlighted Patient Information Leaflet of the month (see article O1).\n\n \n\nArticle citation: Drug Safety Update Oct 2010, vol 4 issue 3: A1.\n"
}